Our analyses show that GLP-1 RAs used for weight reduction in people with overweight and obesity result in a net benefit in achieving a 10% weight loss during the initial phases of treatment, particularly in the first and second year. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.